CAD & Atherosclerosis
20th Anniversary
20 years of clinical research in cardiology
“It’s unbelievable how much we’ve accomplished in the last 20 years” in cardiology, said Dr. Steven E. Nissen.
Conference Coverage
Heart-healthy actions promote longer, disease-free life
Stronger measures of cardiovascular health were linked to longer life expectancy and fewer chronic conditions.
Conference Coverage
High CV risk factor burden in young adults a ‘smoldering’ crisis
Cardiovascular risk factors are “unacceptably” high and are increasing among young adults, prompting calls for aggressive preventive measures.
Conference Coverage
COORDINATEd effort boosts optimal therapy in patients with T2D and ASCVD
Conference Coverage
Causal AI quantifies CV risk, providing patient-specific goals
Causal artificial intelligence is showing how specific risk factors can be overcome to avoid cardiovascular events.
From the Journals
Biomarkers linked to elevated T2D MACE risk in DECLARE-TIMI 58
A secondary DECLARE-TIMI 58 trial analysis linked two biomarkers to higher cardiovascular risks in diabetes and found a strong benefit of...
Conference Coverage
BIOVASC: Immediate complete revascularization beneficial in ACS
Immediate complete revascularization during the index procedure might become the new treatment paradigm in patients with ACS and multivessel...
Conference Coverage
When intravascular imaging guides complex PCI, MACE risk is lowered
In stent placement for complex coronary lesions, intravascular imaging reduces events relative to angiography.
Conference Coverage
Viability-guided PCI doubted in stable severe CAD: REVIVED-BCIS2
Is myocardial viability testing for guiding PCI decisions currently used in the best way? A secondary analysis from the main trial suggests not....
Conference Coverage
Bempedoic acid cuts CV events in statin-intolerant patients: CLEAR Outcomes
The CLEAR Outcomes trial establishes this new drug as an important addition to available nonstatin LDL cholesterol–lowering therapies, experts say...
Conference Coverage
At 5 years, TAVI valves perform better than surgical ones
TAVR valves deteriorate less than surgical valves at 5 years in patients treated for severe aortic stenosis.